Axial spondyloarthritis and axial psoriatic arthritis: similar or different disease spectrum?

ABSTRACT:

Aims

First, to compare clinical features and biological disease modifying anti-rheumatic drugs (bDMARDs) response in patients with axial spondyloarthritis (axSpA) and axial psoriatic arthritis (axPsA). Second, to identify possible predictors of treatment response in both entities.

Methods

One-year follow-up, observational, single-center study including all patients with axSpA or axPsA who started bDMARDs therapy. Clinical features were collected at baseline while disease activity was measured at baseline, 6 and 12 months by the Ankylosing Spondylitis Disease Activity Score and the Physician Global Assessment. The frequency of patients achieving inactive disease (ID), low disease activity (LDA), high or very high disease activity and clinical improvement were compared between

SUBMITTER: Benavent D 

PROVIDER: S-EPMC7675867 | biostudies-literature | 2020

REPOSITORIES: biostudies-literature